ZimVie Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

ZimVie şirketinin toplam hissedar öz sermayesi $406.6M ve toplam borcu $220.3M olup, bu da borç-öz sermaye oranını 54.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $782.9M ve $376.3M dir.

Anahtar bilgiler

54.2%

Borç/özkaynak oranı

US$220.28m

Borç

Faiz karşılama oranı	n/a
Nakit	US$66.81m
Eşitlik	US$406.64m
Toplam yükümlülükler	US$376.31m
Toplam varlıklar	US$782.95m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade)

Jun 04

ZimVie: Shrinking Its Way To Profitability

Feb 12

ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry

Dec 19

ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry

Apr 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ZIMV 'nin kısa vadeli varlıkları ( $265.7M ) kısa vadeli yükümlülüklerini ( $136.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: ZIMV şirketinin kısa vadeli varlıkları ( $265.7M ) uzun vadeli yükümlülüklerini ( $239.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ZIMV 'nin net borç/öz sermaye oranı ( 37.7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: ZIMV şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan ZIMV mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: ZIMV kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 57.2 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

ZimVie Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

ZimVie Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

ZimVie Inc. Reiterates Earnings Guidance for the Full Year Ending December 31, 2024

ZimVie Inc. Announces the Release of RealGUIDE® 5.4 Software Update

ZimVie Inc. Announces FDA Clearance and U.S. Launch of GenTek Restorative Components

ZimVie Inc. to Report Q2, 2024 Results on Aug 01, 2024

Now 31% overvalued after recent price rise

Now 42% overvalued after recent price rise

Now 21% overvalued

ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade)

President exercised options and sold US$356k worth of stock

ZimVie Inc. Provides Earnings Guidance for the Full Year 2024 Ending December 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ZimVie Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$172k worth of stock

H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV).

ZimVie Inc., Annual General Meeting, May 15, 2024

ZimVie Inc., Annual General Meeting, May 15, 2024

President exercised options and sold US$163k worth of stock

Price target increased by 19% to US$16.00

New minor risk - Shareholder dilution

ZimVie Inc. Provides Earnings Guidance for First Quarter and Raises Earnings Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

ZimVie Inc. to Report Q4, 2023 Results on Feb 28, 2024

ZimVie: Shrinking Its Way To Profitability

ZimVie Inc. Announces Launch of Next-Generation TSX®? Implant in Japan

H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million.

ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry

H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million.

ZimVie Inc. Announces Compatibility Between Its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.032 profit in 3Q 2022)

Zimvie Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

ZimVie Inc. Announces First U.S. Surgery with the 4.5mm Mobi-C(R) Cervical Disc

ZimVie Inc. Announces the Launch of Azure Multi-Platform Product Solutions

ZimVie Inc. to Report Q3, 2023 Results on Nov 01, 2023

ZimVie Inc. Announces the Recent Launch of Biotivity A/C Plus Membrane

ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study

ZimVie Inc. Announces FDA Approval for New Mobi-C(R) Implant

Second quarter 2023 earnings released: US$0.89 loss per share (vs US$0.33 loss in 2Q 2022)

ZimVie Inc. Revises Financial Guidance for the Full Year Ending December 31, 2023

New minor risk - Share price stability

ZimVie Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings released: US$1.14 loss per share (vs US$0.98 loss in 1Q 2022)

Zimvie Inc. Revises Earnings Guidance for the Full Year 2023

ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry

President recently bought US$122k worth of stock

Full year 2022 earnings released: US$2.45 loss per share (vs US$3.66 loss in FY 2021)

ZimVie Inc. to Report Q4, 2022 Results on Mar 01, 2023

ZimVie Inc. Announces Over 200,000 Cervical Discs Have Been Replaced with Mobi-C

High number of new and inexperienced directors

ZimVie Inc. Reaffirms Revenue Guidance for the Year 2022

Zimvie Announces Launch of Next-Generation TSX™ Implant in the United States

ZimVie Inc. to Report Q3, 2022 Results on Nov 09, 2022

Zimvie Expands Navigation-Compatible Platform to Include Posterior Cervical Application

ZimVie Inc.(NasdaqGS:ZIMV) dropped from FTSE All-World Index (USD)

ZimVie: Disappointing Guidance Prompts Caution

Second quarter 2022 earnings released

ZimVie Inc. Revises Net Sales Guidance for the Year 2021

ZimVie Q2 Non-GAAP EPS beats, revenue down Y/Y, guidance reduced

ZimVie Inc. to Report Q2, 2022 Results on Aug 10, 2022

ZimVie: Undervalued Spin-Off

Zimvie Inc. Announces Launch of Two Next-Generation Dental Solutions in the United States

Executive VP recently bought US$205k worth of stock

High number of new and inexperienced directors

ZimVie: Spin-Off Of Dental And Spine Units Of Zimmer Biomet

ZimVie Inc. to Report Q1, 2022 Results on May 05, 2022

Forecast to breakeven in 2022

ZimVie Inc. Provides Revenue Guidance for the Year Ending December 31, 2022

High number of new and inexperienced directors

ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P 500 Health Care (Sector)

ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P Global 1200

ZimVie Inc. Announces Board of Directors

Finansal Durum Analizi